r.rotation.to⌕ Search stocks, people, sectors
Following this device: dark.
Request a free account

Follow the people · Insider

JT

James B. Tananbaum

Insider · Director and 10% owner · LTGO

James B. Tananbaum files insider transactions with the SEC as a director and 10% owner of Latigo Biotherapeutics. We hold 2 disclosed purchases and sales filed since 2 June 2016, 1 of them in the last 90 days.

  • Files for 10 companiesLTGO, ALMS, KNTE, PRDS and 6 more
  • Disclosed buys and sells2 in all, 1 in the last 90 days
  • Last disclosure10 August 2026

Positions held

10 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 10 August 2026 — 10 August 2026Director and 10% owner · Latigo Biotherapeutics 15 Form 4 lines · source: SEC Form 4
  • Filed 1 July 2024 — 1 April 2026Director and 10% owner · Alumis 47 Form 4 lines · source: SEC Form 4
  • Filed 2 December 2020 — 3 April 2024Director and 10% owner · Kinnate Biopharma 25 Form 4 lines · source: SEC Form 4
  • Filed 8 June 2022 — 1 June 2023Director and 10% owner · Pardes Biosciences 4 Form 4 lines · source: SEC Form 4
  • Filed 1 November 2021 — 1 November 202110% owner · Aclaris Therapeutics 2 Form 4 lines · source: SEC Form 4
  • Filed 5 February 2021 — 4 October 2021Director and 10% owner · Gemini Therapeutics, Inc. /DE 4 Form 4 lines · source: SEC Form 4
  • Filed 10 June 2021 — 11 June 2021Director · Quantum-Si 7 Form 4 lines · source: SEC Form 4
  • Filed 14 August 2020 — 14 August 2020President & CEO · FS Development 1 Form 4 line · source: SEC Form 4
  • Filed 6 October 2016 — 20 December 201910% owner · Aerie Pharmaceuticals 13 Form 4 lines · source: SEC Form 4
  • Filed 31 May 2016 — 31 May 201610% owner · Aimmune Therapeutics 2 Form 4 lines · source: SEC Form 4

Every transaction

120 transactions from SEC Form 4 — one row each, sort any column, open a row for the filing
120 of 120 shown
10 Aug 202610 Aug 2026SEC Form 40 dconvertednot a tradeLatigo Biotherapeutics3,117,664 sharesup +22.8%up +22.8%
10 Aug 202610 Aug 2026SEC Form 40 dconvertednot a tradeLatigo Biotherapeuticsderivative445,320 sharesup +22.8%up +22.8%
10 Aug 202610 Aug 2026SEC Form 40 dconvertednot a tradeLatigo Biotherapeuticsderivative1,125,823 sharesup +22.8%up +22.8%
10 Aug 202610 Aug 2026SEC Form 40 dconvertednot a tradeLatigo Biotherapeuticsderivative742,201 sharesup +22.8%up +22.8%
10 Aug 202610 Aug 2026SEC Form 40 dconvertednot a tradeLatigo Biotherapeuticsderivative3,117,664 sharesup +22.8%up +22.8%
10 Aug 202610 Aug 2026SEC Form 40 dconvertednot a tradeLatigo Biotherapeuticsderivative296,880 sharesup +22.8%up +22.8%
10 Aug 202610 Aug 2026SEC Form 40 dconvertednot a tradeLatigo Biotherapeuticsderivative195,776 sharesup +22.8%up +22.8%
10 Aug 202610 Aug 2026SEC Form 40 dconvertednot a tradeLatigo Biotherapeutics445,320 sharesup +22.8%up +22.8%
10 Aug 202610 Aug 2026SEC Form 40 dconvertednot a tradeLatigo Biotherapeutics1,125,823 sharesup +22.8%up +22.8%
10 Aug 202610 Aug 2026SEC Form 40 dconvertednot a tradeLatigo Biotherapeutics742,201 sharesup +22.8%up +22.8%
10 Aug 202610 Aug 2026SEC Form 40 dbought on the open marketLatigo Biotherapeutics140,000 sharesup +22.8%up +22.8%
10 Aug 202610 Aug 2026SEC Form 40 dconvertednot a tradeLatigo Biotherapeutics195,776 sharesup +22.8%up +22.8%
10 Aug 202610 Aug 2026SEC Form 40 dconvertednot a tradeLatigo Biotherapeutics3,117,664 sharesup +22.8%up +22.8%
10 Aug 202610 Aug 2026SEC Form 40 dconvertednot a tradeLatigo Biotherapeutics296,880 sharesup +22.8%up +22.8%
10 Aug 202610 Aug 2026SEC Form 40 dconvertednot a tradeLatigo Biotherapeuticsderivative3,117,664 sharesup +22.8%up +22.8%
1 Apr 20263 Apr 2026SEC Form 42 dacquired or disposed of, othernot a tradeAlumis1,176,470 sharesdown −56.9%down −58.1%
1 Apr 20263 Apr 2026SEC Form 42 dacquired or disposed of, othernot a tradeAlumis1,123,337 sharesdown −56.9%down −58.1%
1 Apr 20263 Apr 2026SEC Form 42 dacquired or disposed of, othernot a tradeAlumis1,123,337 sharesdown −56.9%down −58.1%
1 Apr 20263 Apr 2026SEC Form 42 dacquired or disposed of, othernot a tradeAlumis680,486 sharesdown −56.9%down −58.1%
8 Jan 202612 Jan 2026SEC Form 44 dbought on the open marketAlumis117,647 sharesdown −46.1%down −53.5%
8 Jan 202612 Jan 2026SEC Form 44 dbought on the open marketAlumis294,117 sharesdown −46.1%down −53.5%
8 Jan 202612 Jan 2026SEC Form 44 dbought on the open marketAlumis117,647 sharesdown −46.1%down −53.5%
8 Jan 202612 Jan 2026SEC Form 44 dbought on the open marketAlumis294,117 sharesdown −46.1%down −53.5%
21 Nov 202525 Nov 2025SEC Form 44 dbought on the open marketAlumis72,212 sharesup +34.2%up +33.7%
19 Nov 202519 Nov 2025SEC Form 40 dbought on the open marketAlumis190,500 sharesup +49.2%up +49.2%
18 Nov 202519 Nov 2025SEC Form 41 dbought on the open marketAlumis117,374 sharesup +52.9%up +49.2%
17 Nov 202519 Nov 2025SEC Form 42 dbought on the open marketAlumis50,000 sharesup +75.8%up +49.2%
17 Nov 202519 Nov 2025SEC Form 42 dbought on the open marketAlumis150,000 sharesup +75.8%up +49.2%
6 May 20256 May 2025SEC Form 40 dbought on the open marketAlumis20,000 sharesup +125.3%up +125.3%
2 May 20256 May 2025SEC Form 44 dbought on the open marketAlumis25,000 sharesup +113.5%up +125.3%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumisderivative1,944,577 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumisderivative194,459 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumisderivative1,122,994 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumisderivative481,283 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumisderivative560,076 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumisderivative560,076 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumisderivative967,567 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumisderivative622,344 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumisderivative311,172 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumisderivative311,172 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumisderivative311,172 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumisderivative1,022,398 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumisderivative681,598 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumisderivative1,703,998 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumisderivative681,598 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumis1,944,577 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumis1,122,994 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumis560,076 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumis622,344 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumis1,022,398 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dbought on the open marketAlumis312,500 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumis194,459 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumis481,283 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumis560,076 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumis311,172 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumis681,598 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumis967,567 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumis311,172 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumis681,598 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumis311,172 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dconvertednot a tradeAlumis1,703,998 sharesdown −21.9%down −15.9%
1 Jul 20243 Jul 2024SEC Form 42 dbought on the open marketAlumis2,187,500 sharesdown −21.9%down −15.9%
3 Apr 20245 Apr 2024SEC Form 42 dreturned to the issuernot a tradeKNTEKinnate Biopharmaderivative40,501 shares——
3 Apr 20245 Apr 2024SEC Form 42 dreturned to the issuernot a tradeKNTEKinnate Biopharmaderivative20,250 shares——
3 Apr 20245 Apr 2024SEC Form 42 dreturned to the issuernot a tradeKNTEKinnate Biopharma9,671,643 shares——
3 Apr 20245 Apr 2024SEC Form 42 dreturned to the issuernot a tradeKNTEKinnate Biopharma3,525,957 shares——
3 Apr 20245 Apr 2024SEC Form 42 dreturned to the issuernot a tradeKNTEKinnate Biopharma520,711 shares——
1 Jun 20232 Jun 2023SEC Form 41 dwas grantednot a tradePRDSPardes Biosciencesderivative37,500 shares——
8 May 202310 May 2023SEC Form 42 dbought on the open marketKNTEKinnate Biopharma1,550,956 shares——
8 May 202310 May 2023SEC Form 42 dbought on the open marketKNTEKinnate Biopharma229,044 shares——
5 Apr 20236 Apr 2023SEC Form 41 dbought on the open marketPRDSPardes Biosciences773,952 shares——
17 Feb 202322 Feb 2023SEC Form 45 dacquired or disposed of, othernot a tradeKNTEKinnate Biopharma1,100,000 shares——
1 Dec 20225 Dec 2022SEC Form 44 dbought on the open marketPRDSPardes Biosciences637,420 shares——
13 Jun 202215 Jun 2022SEC Form 42 dwas grantednot a tradeKNTEKinnate Biopharmaderivative20,250 shares——
8 Jun 202210 Jun 2022SEC Form 42 dwas grantednot a tradePRDSPardes Biosciencesderivative37,500 shares——
1 Nov 20213 Nov 2021SEC Form 42 dacquired or disposed of, othernot a tradeAclaris Therapeutics1,954,904 sharesdown −69.9%down −65.7%
1 Nov 20213 Nov 2021SEC Form 42 dacquired or disposed of, othernot a tradeAclaris Therapeutics8,276 sharesdown −69.9%down −65.7%
4 Oct 20216 Oct 2021SEC Form 42 dwas grantednot a tradeGMTXGemini Therapeutics, Inc. /DEderivative17,245 shares——
11 Jun 202114 Jun 2021SEC Form 43 dwas grantednot a tradeQuantum-Si20,512 sharesdown −92.3%down −91.2%
10 Jun 202114 Jun 2021SEC Form 44 dwas grantednot a tradeQuantum-Si4,463,619 sharesdown −93.0%down −91.2%
10 Jun 202114 Jun 2021SEC Form 44 dwas grantednot a tradeQuantum-Si743,936 sharesdown −93.0%down −91.2%
10 Jun 202114 Jun 2021SEC Form 44 dwas grantednot a tradeQuantum-Si1,250,000 sharesdown −93.0%down −91.2%
10 Jun 202114 Jun 2021SEC Form 44 dwas grantednot a tradeQuantum-Si348,125 sharesdown −93.0%down −91.2%
10 Jun 202114 Jun 2021SEC Form 44 dwas grantednot a tradeQuantum-Si1,250,000 sharesdown −93.0%down −91.2%
10 Jun 202114 Jun 2021SEC Form 44 dwas grantednot a tradeQuantum-Si348,125 sharesdown −93.0%down −91.2%
5 Feb 20219 Feb 2021SEC Form 44 dconvertednot a tradeGMTXGemini Therapeutics, Inc. /DEderivative2,928,750 shares——
5 Feb 20219 Feb 2021SEC Form 44 dwas grantednot a tradeGMTXGemini Therapeutics, Inc. /DE1,500,000 shares——
5 Feb 20219 Feb 2021SEC Form 44 dconvertednot a tradeGMTXGemini Therapeutics, Inc. /DE2,928,750 shares——
7 Dec 20209 Dec 2020SEC Form 42 dconvertednot a tradeKNTEKinnate Biopharmaderivative6,347,893 shares——
7 Dec 20209 Dec 2020SEC Form 42 dconvertednot a tradeKNTEKinnate Biopharmaderivative298,465 shares——
7 Dec 20209 Dec 2020SEC Form 42 dconvertednot a tradeKNTEKinnate Biopharmaderivative99,488 shares——
7 Dec 20209 Dec 2020SEC Form 42 dconvertednot a tradeKNTEKinnate Biopharmaderivative2,666,002 shares——
7 Dec 20209 Dec 2020SEC Form 42 dconvertednot a tradeKNTEKinnate Biopharmaderivative55,922 shares——
7 Dec 20209 Dec 2020SEC Form 42 dconvertednot a tradeKNTEKinnate Biopharmaderivative18,641 shares——
7 Dec 20209 Dec 2020SEC Form 42 dconvertednot a tradeKNTEKinnate Biopharmaderivative157,222 shares——
7 Dec 20209 Dec 2020SEC Form 42 dconvertednot a tradeKNTEKinnate Biopharmaderivative145,128 shares——
7 Dec 20209 Dec 2020SEC Form 42 dconvertednot a tradeKNTEKinnate Biopharmaderivative48,376 shares——
7 Dec 20209 Dec 2020SEC Form 42 dconvertednot a tradeKNTEKinnate Biopharma9,171,643 shares——
7 Dec 20209 Dec 2020SEC Form 42 dconvertednot a tradeKNTEKinnate Biopharma500,001 shares——
7 Dec 20209 Dec 2020SEC Form 42 dconvertednot a tradeKNTEKinnate Biopharma166,667 shares——
3 Dec 20204 Dec 2020SEC Form 41 dbought on the open marketKNTEKinnate Biopharma500,000 shares——
3 Dec 20204 Dec 2020SEC Form 41 dbought on the open marketKNTEKinnate Biopharma375,000 shares——
3 Dec 20204 Dec 2020SEC Form 41 dbought on the open marketKNTEKinnate Biopharma125,000 shares——
2 Dec 20204 Dec 2020SEC Form 42 dwas grantednot a tradeKNTEKinnate Biopharmaderivative40,501 shares——
14 Aug 202019 Oct 2020SEC Form 466 dbought on the open marketFSDCFS Development441,500 shares——
20 Dec 201923 Dec 2019SEC Form 43 dexercised in-the-money optionsnot a tradeAERIAerie Pharmaceuticalsderivative289 shares——
20 Dec 201923 Dec 2019SEC Form 43 dexercised in-the-money optionsnot a tradeAERIAerie Pharmaceuticals28,900 shares——
3 Sep 20194 Sep 2019SEC Form 41 dbought on the open marketAERIAerie Pharmaceuticals34,900 shares——
3 Sep 20194 Sep 2019SEC Form 41 dbought on the open marketAERIAerie Pharmaceuticals15,100 shares——
30 Aug 20194 Sep 2019SEC Form 45 dbought on the open marketAERIAerie Pharmaceuticals25,000 shares——
14 Aug 201914 Aug 2019SEC Form 40 dbought on the open marketAERIAerie Pharmaceuticals100,000 shares——
13 Aug 201914 Aug 2019SEC Form 41 dbought on the open marketAERIAerie Pharmaceuticals71,097 shares——
13 Aug 201914 Aug 2019SEC Form 41 dbought on the open marketAERIAerie Pharmaceuticals178,903 shares——
12 Aug 201914 Aug 2019SEC Form 42 dbought on the open marketAERIAerie Pharmaceuticals189,555 shares——
26 May 201731 May 2017SEC Form 45 dsold on the open marketAERIAerie Pharmaceuticals9,818 shares——
26 May 201731 May 2017SEC Form 45 dsold on the open marketAERIAerie Pharmaceuticals10,182 shares——
6 Oct 201611 Oct 2016SEC Form 45 dsold on the open marketAERIAerie Pharmaceuticals24,813 shares——
6 Oct 201611 Oct 2016SEC Form 45 dsold on the open marketAERIAerie Pharmaceuticals25,187 shares——
31 May 20162 Jun 2016SEC Form 42 dsold on the open marketAIMTAimmune Therapeutics120,000 shares——
31 May 20162 Jun 2016SEC Form 42 dsold on the open marketAIMTAimmune Therapeutics120,000 shares——

Both percentages are the stock’s move, not James B. Tananbaum’s return: a disclosure gives a band, never an amount, so nobody can say how much was bought or what it made. They run to the last close we hold — 9 Sep 2026, except where a name has since delisted, when the row names its own last session. We publish no close, no volume and no dollar figure behind them. 71 of the 120 rows shown carry a percentage; the rest are dashes with the reason on the row.

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.

Some filings reach us as photographs of paper rather than as a form we can read as text. Those are shown here only once they have been read and checked, so this page can hold fewer lines than the filings behind it contain. The link on every row opens the original document, which is always the full record.